Merck KGaA, Darmstadt, Germany, is preparing strategic options for its Consumer Health business, including a potential full or partial sale of the business as well as strategic partnerships.
 
Merck KGaA, Darmstadt, Germany, is preparing strategic options for its Consumer Health business, including a potential full or partial sale of the business as well as strategic partnerships.
 
“We have continued to transform Merck KGaA, Darmstadt, Germany, over the last years into a leading science and technology company. Healthcare largely focuses on its Biopharma pipeline,” said Stefan Oschmann, chairman of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany.
 
“Our Consumer Health portfolio has been continuously enhanced over the past years. We have maintained a solid position in attractive markets, and demonstrated a pattern of profitable growth. We expect increasing internal constraints to fund the business to reach the required scale. Fully anticipating this, we are preparing strategic options,” said Belén Garijo, member of the Executive Board of Merck KGaA, Darmstadt, Germany and CEO Healthcare.
 
Consumer Health is running a strong international business with a number of leading products in Over-the-Counter (OTC) categories. The business focuses on consumer-centric solutions driven by global megatrends and achieved net sales of €860 million in 2016.
 
Merck KGaA, Darmstadt, Germany, has consistently shifted towards becoming a leading science and technology company. Key milestones such as the acquisitions of Sigma-Aldrich, AZ Electronic Materials and Millipore, the divestment of its Biosimilars business as well as the ongoing strategic portfolio shift within the Healthcare business sector have supported this strategy.